curasan AG to Invest Approximately 1 Million Euros in Future Growth – Product Pipeline Well Filled
curasan AG is to invest in its future growth by implementing a technological investment programme amounting to approximately 1 million euros, despite the current crisis in the financial markets
Kleinostheim, Germany, October 14, 2009 --(PR.com)-- curasan AG, which is listed on the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), is to invest in its future growth by implementing a technological investment programme amounting to approximately 1 million euros, despite the current crisis in the financial markets.
The aim of the investment package is to significantly strengthen and expand the company’s research, development and production capacities and to integrate modern technologies. Part of this strategy will involve relocating the Frankfurt production and development centre to larger premises in the immediate vicinity of the current location. The relocation will take place step by step and is scheduled to be completed by mid-2010.
“We have a wide range of products that will be ready for market launch in the near future and this investment is therefore necessary in order to be able to provide sufficient supplies to future sales partners”, explains Hans Dieter Rössler, Chairman of the Management Board.
Two of the new products will be ready for the market later this year: towards the end of 2009, curasan AG will enter into negotiations regarding the award of a sales licence for a product that helps to retrieve autologous (patient’s own) growth factors (ATR®). A further product, Osbone®, will be ready for licensing this year. This is a synthetically manufactured, non-resorbant bone replacement material.
The development of a paste version of Cerasorb® could also be pushed forwards during 2009. For physicians, this pharmaceutical form is easier to handle than granulates when used in places that are difficult to access (“bone out of a syringe”). The production of pilot batches, as well as the creation of all the documentation required for approval, is planned for 2010.
The focus of curasan AG medical products currently on the market is the area of biomaterials. This includes products for bone replacement (Cerasorb®), osteoarthritis (Curavisc®) and haemostasis (stypro®). In the pharmaceutical sector, curasan AG supplies a medication for the treatment of superficial bladder carcinomas (Mitem®), which is marketed and sold by Schwarz Pharma AG / UCB-Group.
“We are forecasting continued growth in the future”, states Hans Dieter Rössler, Chairman of the curasan AG Management Board.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
Press Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de
###
The aim of the investment package is to significantly strengthen and expand the company’s research, development and production capacities and to integrate modern technologies. Part of this strategy will involve relocating the Frankfurt production and development centre to larger premises in the immediate vicinity of the current location. The relocation will take place step by step and is scheduled to be completed by mid-2010.
“We have a wide range of products that will be ready for market launch in the near future and this investment is therefore necessary in order to be able to provide sufficient supplies to future sales partners”, explains Hans Dieter Rössler, Chairman of the Management Board.
Two of the new products will be ready for the market later this year: towards the end of 2009, curasan AG will enter into negotiations regarding the award of a sales licence for a product that helps to retrieve autologous (patient’s own) growth factors (ATR®). A further product, Osbone®, will be ready for licensing this year. This is a synthetically manufactured, non-resorbant bone replacement material.
The development of a paste version of Cerasorb® could also be pushed forwards during 2009. For physicians, this pharmaceutical form is easier to handle than granulates when used in places that are difficult to access (“bone out of a syringe”). The production of pilot batches, as well as the creation of all the documentation required for approval, is planned for 2010.
The focus of curasan AG medical products currently on the market is the area of biomaterials. This includes products for bone replacement (Cerasorb®), osteoarthritis (Curavisc®) and haemostasis (stypro®). In the pharmaceutical sector, curasan AG supplies a medication for the treatment of superficial bladder carcinomas (Mitem®), which is marketed and sold by Schwarz Pharma AG / UCB-Group.
“We are forecasting continued growth in the future”, states Hans Dieter Rössler, Chairman of the curasan AG Management Board.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
Press Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de
###
Contact
curasan AG
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Contact
Categories